YAYvonne Awenat

Yvonne Awenat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yvonne Awenat has a total of 113 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel Pratt

    Division of Psychology and Mental Health, School of Health Sciences, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK

    18 shared publications
  • Patricia Gooding

    Division of Psychology and Mental Health, School of Health Sciences, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK

    12 shared publications
  • Gillian Haddock

    Division of Psychology and Mental Health, School of Health Sciences, University of Manchester and the Manchester Academic Health Sciences Centre, Manchester, UK

    9 shared publications
  • Charlotte Huggett

    Division of Psychology and Mental Health, School of Health Sciences, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK

    5 shared publications
  • Gillian Haddock

    Division of Psychology and Mental Health, School of Health Sciences, Manchester Academic Health Sciences Centre, University of Manchester, Coupland Building 1, Oxford Road, Manchester, M13 9PL, UK

    5 shared publications
  • Nicholas Tarrier

    King’s College London

    5 shared publications

Latest Publications

  • Open Access

    A Qualitative Co‐Production Study of a Solutions‐Focused Approach to Understanding the Barriers and Facilitators to Engagement of Male Suicidal Prisoners in Psychological Therapy for Suicide Prevention

    byĀ Yvonne Awenat, Rebecca Crook, David Honeywell, Charlotte Lennox, Dawn Edge, Patrcia Gooding, Gillian Haddock, Helen Brooks, Caroline Hendricks, Daniel Pratt

    Introduction: Psychological therapies are rarely available for UK suicidal prisoners. A pilot feasibility clinical trial of Cognitive Behavioural Suicide Prevention therapy showed that it was possible to deliver therapy offering the potential to improve outcomes for suicidal prisoners. However, there were challenges to engaging male prisoners in therapy as many experienced difficulties in accessing and talking about their emotions. Difficulty in talking about emotions is common amongst male prisoners, yet this is essential for successful engagement in a talking therapy. The current co‐production study aimed to further understand the contextual influences that impact male prisoners' ability to engage with a psychological intervention focused on suicide prevention and to explore user‐generated solutions. Methods: Community‐residing male ex‐prisoners with past experience of suicidal thoughts or behaviour during imprisonment participated in individual qualitative interviews followed by a series of six focus groups. Due to COVID‐19 restrictions in place at that time, recruitment and data collection were conducted by remote methods. Data were analysed according to the principles of reflexive thematic analysis. Results: Fifteen individuals participated: twelve completed individual interviews, ten participated in the focus groups, with seven individuals participating in both. Three main themes were formed. 1. Negotiating prison personas and identities – Pressures to hide emotions, act tough, and distrust professionals. 2. Command and control in prison – Prison regimes impact on interpersonal relationships with staff and other prisoners to worsen suicide risk, with prisoner's healthcare needs often neglected. 3. Making therapy accessible and acceptable – Prisoners must be able to trust a compassionate therapist for engagement to be successful. Conclusion: This study epitomises the feasibility and value of meaningful co‐production in research involving populations from marginalised groups such as ex‐prisoners. Our results reveal how the combination of individual prisoner and prison institution socio‐cultural contextual influences impact suicidal prisoners' engagement in psychotherapy. User‐defined suggestions are provided to promote development of potential remedies. Patient or Public Contribution: Co‐production was achieved by the leading role of a salaried peer‐researcher co‐investigator in liaison with members of our Suicide Risk and Safety Research Group (SSRG) comprised of Experts‐by‐Experience (EbEs). Co‐decision making featured throughout all stages of the research, influencing the protocol design and interview schedule. The personal experience knowledge of the peer‐researcher/co‐investigator enabled targeted recruitment strategies and successful engagement of participants. Shared past experiences of prison life and language positively influenced rapport and engagement of participants during data collection, enabling attainment of rich data. Similarly, the peer researcher/co‐investigator's unique personal experiential knowledge ensured a ā€˜real‐world’ perspective to analysis and co‐authorship of publications.

  • Open Access

    A psychological talking therapy for suicidality in people experiencing non-affective psychosis: Mechanism and efficacy outcomes of the CARMS (Cognitive AppRoaches to coMbatting Suicidality) randomised controlled trial

    byĀ Patricia Gooding, Yvonne Awenat, Richard Drake, Richard Emsley, Steven Jones, Navneet Kapur, Fiona Lobban, Sarah Peters, Daniel Pratt, Rachel Elliott, et al.

    Background: Suicide is a leading cause of death worldwide, particularly in people with severe mental health problems, including schizophrenia. The development, and testing, of suicide-focused psychological interventions which can combat suicidal experiences is an unrealised necessity. However, it is vital that suicide-focused therapies are derived from robust, evidence-based mechanistic suicide theories. The Schematic Appraisals Model of Suicide is one such theory. Objective(s): The Cognitive AppRoaches to coMbatting Suicidality project had two objectives. First, based on the Schematic Appraisals Model of Suicide, to test psychological pathways underlying suicidal thoughts, plans and attempts. Second, to test the efficacy of Cognitive–Behavioural Suicide Prevention for psychosis, a suicide-focused intervention developed by our team. Design: The randomised controlled trial had two groups: our suicide-focused therapy, Cognitive–Behavioural Suicide Prevention adapted Cognitive–Behavioural Suicide Prevention for psychosis, plus treatment as usual (treatment) versus treatment as usual only (control). There were three assessment time points of baseline, 6 and 12 months, with the 6-month time point being the critical point for the main primary outcome. Four qualitative methods workstreams were nested within the randomised controlled trial design. Settings: Four National Health Service Trust sites in the North West of England, United Kingdom: Greater Manchester Mental Health NHS Foundation Trust, Pennine Care NHS Foundation Trust, Lancashire and South Cumbria NHS Foundation Trust, and the former North West Boroughs Healthcare NHS Foundation Trust. Participants: Main inclusion criteria: (1) non-affective psychosis (e.g. schizophrenia), (2) suicidal experiences in the 3 months prior to recruitment; (3) under the care of an National Health Service mental health services team and (iv) aged 18 or over. Main outcome measures: The primary outcome measure was the Adult Suicidal Ideation Questionnaire, which measures suicidal ideation severity over the past month using 25 self-report items. The 6-month follow-up assessment point was the critical time point. There were two secondary suicide measures. Mechanism measures captured six appraisals of emotional difficulties, lack of social support, interpersonal problem-solving difficulties, defeat, entrapment and hopelessness. Results: Recruitment ensued from on 21 June 2017 and lasted until 25 November 2020. The last 12-month follow-up assessment was completed on 10 January 2022. Two hundred and ninety-two participants were randomly allocated to the treatment ( N = 149) and control ( N = 143) groups. Reductions in suicidal ideation severity were not significantly greater in the treatment compared to the control group ( p = 0.07; 95% confidence interval āˆ’15.41 to 0.68) at month 6. There were, similarly, no significant treatment effects for the secondary suicide outcomes. A therapy ā€˜dose–response’ showed that each therapy session reduced the suicidal ideation severity score by 0.46, but this effect was also not significant ( p = 0.056; 95% confidence interval āˆ’0.94 to 0.01), nor was a compliance-adjusted analysis in which only participants who attended at least one session of therapy were included ( p = 0.052; 95% confidence interval āˆ’0.39 to 0.00). However, a predicted mediation pathway was statistically significant for one of the six mechanism measures, in which the therapy group relative to the control group improved social support appraisals, which, in turn, reduced suicidal ideation severity at month 6 (effect = āˆ’2.85, 95% confidence interval āˆ’7.00 to āˆ’0.23). Qualitative and mixed-methods findings showed that (1) feelings of not mattering, disconnection and irrelevance were central to suicidal thoughts, (2) it is vital to develop better ways of communicating about suicide, (3) our suicide-focused therapy was acceptable and feasible and (4) that being part of suicide work in a trial was largely a positive experience. Limitations: The sample was predominantly White/Caucasian and conducted in one geographical United Kingdom location, the primary outcome measure captured only suicidal thought severity, and there were only two follow-up time points. Conclusions: This suicide-focused psychological intervention did not demonstrate a treatment effect in the primary suicide outcome measure at month 6 at the 5% significance threshold. There was also no significant treatment effect for secondary suicide outcomes. Future work: Research programmes founded on convergent methods, and evidenced-based psychological suicide models are needed to examine how to bolster appraisals of poor social support, disconnection, and not mattering in the context of suicidal mind-sets, and in tandem with the development of creative and inclusive communication tools to relay suicidal experiences. In addition, exploration of the role of ā€˜dose’ of therapy is crucial for further treatment development. Trial registration: This trial is registered as ClinicalTrials.gov NCT03114917 and ISRCTN17776666. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 13/161/25) and is published in full in Efficacy and Mechanism Evaluation ; Vol. 13, No. 3. See the NIHR Funding and Awards website for further award information.

  • Open Access

    Psychological therapy for the prevention of suicide in prison: study protocol for a randomised controlled trial

    byĀ Daniel Pratt, Tim Kirkpatrick, Yvonne Awenat, Caroline Hendricks, Amanda Perry, Leslie-Anne Carter, Rebecca Crook, Paula Duxbury, Charlotte Lennox, Sarah Knowles, et al.

    Background: Suicide is the leading cause of preventable death in prisons. Deaths from suicide in prison are significantly, and persistently, elevated compared to those living in the community. Psychological therapies have been shown to be a potentially effective means of alleviating suicidal thoughts, plans and behaviours, but patients located in prison often have no access to evidence-based psychological interventions targeting suicide. The objectives of this programme of research are to investigate the clinical and cost effectiveness of a new psychological therapy programme delivered to male prisoners at risk of suicide. Methods: The PROSPECT trial is a two-armed single blind, pragmatic, randomised controlled trial and will recruit a target sample size of 360 male prisoners, identified as at-risk of suicide, across 4 prisons in the North of England. Participants will be randomised to receive a psychological talking therapy (Cognitive Behavioural Suicide Prevention, CBSP) plus treatment as usual, or treatment as usual alone. Co-primary outcomes (Suicide Ideation and Suicide Behaviours), as well as related secondary outcomes, will be assessed at baseline and at 6-months follow-up. An intention to treat analysis will be conducted with primary stratification based on prison site and lifetime history of suicide attempt (yes/no). A nested qualitative process evaluation will investigate the nature and context in which the intervention is delivered, with specific focus upon the facilitators and barriers to the implementation of the therapy within prisons. Discussion: The key outputs from this trial will be to determine whether a psychological therapy for suicidal prisoners is clinically and cost effective; and to generate a project implementation platform that identifies how best to implement the new intervention across the broader prison estate. Trial registration: ISRCTN (reference ISRCTN14056534 https://www.isrctn.com/ISRCTN14056534; 24th September 2021). Registration confirmed prior to participant recruitment commencing. Modifications to protocol are listed on the study website at ISRCTN.


  • Intensive Cognitive Behaviour Suicide Prevention for Males in Custody: A Pilot Feasibility Case Series

    byĀ Lauren Hampson, Charlotte Lennox, Jessica Killilea, Yvonne Awenat, Daniel Pratt

    Retention of participants to programs of psychological therapy in a prison setting is problematic. Intensively delivered therapy has emerged in recent years, in contrast to the traditional format of weekly sessions of psychological therapy. This study aimed to evaluate the feasibility of an intensive program of cognitive behavior suicide prevention therapy within a male prison, for the first time. Thirteen participants consented to take part. Up to 10 h of therapy was offered, across five sessions, within a 3-week delivery window. Outcome measures were completed at baseline and follow-up. Program completion and client satisfaction with the intensive program were high. Outcomes related to suicidal distress were assessed, with effect sizes reported. Large and statistically significant effect sizes were found for suicidal ideation and emotional regulation when comparing baseline to follow-up. Small and non-significant effects were found for social support and problem solving when comparing the same. The study holds promise for the feasibility and efficacy of delivering an intensive cognitive behavior suicide prevention therapy for people in prison. Further exploration on a larger scale is warranted [Clinical Trial ID: NCT03499548].


  • Open Access

    A psychological intervention for suicide applied to non-affective psychosis: the CARMS (Cognitive AppRoaches to coMbatting Suicidality) randomised controlled trial protocol

    byĀ Patricia A. Gooding, Daniel Pratt, Yvonne Awenat, Richard Drake, Rachel Elliott, Richard Emsley, Charlotte Huggett, Steven Jones, Navneet Kapur, Fiona Lobban, et al.

    Background: Suicide is a leading cause of death globally. Suicide deaths are elevated in those experiencing severe mental health problems, including schizophrenia. Psychological talking therapies are a potentially effective means of alleviating suicidal thoughts, plans, and attempts. However, talking therapies need to i) focus on suicidal experiences directly and explicitly, and ii) be based on testable psychological mechanisms. The Cognitive AppRoaches to coMbatting Suicidality (CARMS) project is a Randomised Controlled Trial (RCT) which aims to investigate both the efficacy and the underlying mechanisms of a psychological talking therapy for people who have been recently suicidal and have non-affective psychosis.Methods: The CARMS trial is a two-armed single-blind RCT comparing a psychological talking therapy (Cognitive Behavioural Suicide Prevention for psychosis [CBSPp]) plus Treatment As Usual (TAU) with TAU alone. There are primary and secondary suicidality outcome variables, plus mechanistic, clinical, and health economic outcomes measured over time. The primary outcome is a measure of suicidal ideation at 6 months after baseline. The target sample size is 250, with approximately 125 randomised to each arm of the trial, and an assumption of up to 25% attrition. Hence, the overall recruitment target is up to 333. An intention to treat analysis will be used with primary stratification based on National Health Service (NHS) recruitment site and antidepressant prescription medication. Recruitment will be from NHS mental health services in the North West of England, UK. Participants must be 18 or over; be under the care of mental health services; have mental health problems which meet ICD-10 non-affective psychosis criteria; and have experienced self-reported suicidal thoughts, plans, and/or attempts in the 3 months prior to recruitment. Nested qualitative work will investigate the pathways to suicidality, experiences of the therapy, and identify potential implementation challenges beyond a trial setting as perceived by numerous stake-holders.Discussion: This trial has important implications for countering suicidal experiences for people with psychosis. It will provide definitive evidence about the efficacy of the CBSPp therapy; the psychological mechanisms which lead to suicidal experiences; and provide an understanding of what is required to implement the intervention into services should it be efficacious.Trial registration: ClinicalTrials.gov(NCT03114917), 14th April 2017. ISRCTN (reference ISRCTN1777666610.1186/ISRCTN17776666); 5th June 2017). Registration was recorded prior to participant recruitment commencing.


  • Open Access

    Qualitative analysis of ward staff experiences during research of a novel suicide-prevention psychological therapy for psychiatric inpatients: Understanding the barriers and facilitators

    byĀ Yvonne F Awenat, Sarah Peters, Patricia A Gooding, Daniel Pratt, Charlotte Huggett, Kamelia Harris, Christopher J Armitage, Gillian Haddock

    Suicide prevention is a global priority. Psychiatric hospitalization presents an opportunity to intervene positively with, for example, psychological therapies. However, evidenced-based suicide-prevention psychological treatments are rarely available on in-patient wards. Understanding staff engagement with research investigating suicide-prevention psychological treatments is crucial for their effective, efficacious, and pragmatic implementation. A pilot randomised control trial and feasibility study of Cognitive Behavioural Suicide Prevention therapy provided the opportunity for a qualitative investigation of staff experiences and views of a psychological intervention for people with suicidal experiences on psychiatric in-patient wards. To investigate staff acceptability of Cognitive Behavioural Suicide Prevention therapy for psychiatric inpatients based on their perceptions of their experiences during the conduct of a clinical trial. Transcribed audio-recordings of qualitative interviews and a focus group (n = 19) of purposively sampled staff from eight psychiatric wards were analysed using inductive Thematic Analysis. Facilitators and barriers were identified for: i) the conduct of the research, and, ii) the suicide-prevention intervention (Cognitive Behavioural Suicide Prevention therapy). Research-related barriers comprised communication difficulties between staff and researchers, and increased staff workload. Research-related facilitators included effective staff/researcher relationships, and alignment of the intervention with organisational goals. Suicide-prevention intervention-related barriers comprised staffs’ negative beliefs about suicide which impacted on their referral of inpatients to the clinical trial, and staff perceptions of insufficient information and unfulfilled expectations for involvement in the therapy. Facilitators included staff beliefs that the therapy was beneficial for inpatients, the service and their own clinical practice. Staff beliefs that ā€˜suicide-talk’ could precipitate suicidal behaviour resulted in covert gatekeeping and restricted referral of only inpatients judged as stable or likely to engage in therapy, which may not be those who could most benefit. Such threats to sample representativeness have implications for future therapy research design. The findings provide novel information for researchers and practitioners regarding the conduct of psychological treatment and research in psychiatric units.


  • A pilot study exploring the utility of a ā€˜therapeutic research group’ intervention for people experiencing psychosis related difficulties.

    byĀ M. Abram, Y. Awenat, R. Byrne, M. Fin, S. Finlayson, G. Foat-Smith, M. Galarza, G. Haddock, P. Jackson, G. Lee, et al.

    Objectives: This pilot study explored the feasibility and acceptability of using research as the basis of a therapeutic group intervention for hearing voices/auditory hallucinations. Methods: Using a Participatory Action Research methodology, seven male current or previous residents of a low secure hospital participated in the study. Participants independently conducted research on ideas that were generated and operationalised by the group, on a weekly basis over a seven-month period. Participants focused on developing a new ā€˜easy to complete’ recovery/resilience measure. The group also themselves developed a qualitative interview schedule, and participated in interviews at the conclusion of the intervention period. In addition to the four participants who engaged throughout the intervention period and contributed towards the analysis of transcripts, three other participant’s (two who disengaged on moving to a new area and one who consented to participate but never attended) took part in post-intervention interviews. Results: The study demonstrated preliminary evidence supporting the utility of a ā€˜Therapeutic Research Group’ intervention for people who experience distressing voices. In addition to feedback about the positive impact participating in the group had on well-being, participants offered advice on overcoming barriers and increasing the popularity of therapeutic interventions. Participants also developed a new recovery/resilience measure (the M-PART) whose preliminary face validity appears positive. Discussion: Mental health service users/survivors can independently make important contributions to advancing knowledge and improving services. Further research examining whether ā€˜the conducting of research’ could form the basis of a therapeutic intervention is warranted. Empirical testing of the M-PART measure is also necessary.


  • Open Access

    Feasibility and acceptability of suicide prevention therapy on acute psychiatric wards: randomised controlled trial

    byĀ Gillian Haddock, Daniel Pratt, Patricia A. Gooding, Sarah Peters, Richard Emsley, Emma Evans, James Kelly, Charlotte Huggett, Ailsa Munro, Kamelia Harris, et al.

    Background: Suicidal behaviour is common in acute psychiatric wards resulting in distress, and burden for patients, carers and society. Although psychological therapies for suicidal behaviour are effective in out-patient settings, there is little research on their effectiveness for in-patients who are suicidal.Aims: Our primary objective was to determine whether cognitive–behavioural suicide prevention therapy (CBSP) was feasible and acceptable, compared with treatment as usual (TAU) for in-patients who are suicidal. Secondary aims were to assess the impact of CBSP on suicidal thinking, behaviours, functioning, quality of life, service use, cost-effectiveness and psychological factors associated with suicide.Method: A single-blind pilot randomised controlled trial comparing TAU to TAU plus CBSP in in-patients in acute psychiatric wards who are suicidal (the Inpatient Suicide Intervention and Therapy Evaluation (INSITE) trial, trial registration: ISRCTN17890126). The intervention consisted of TAU plus up to 20 CBSP sessions, over 6 months continuing in the community following discharge. Participants were assessed at baseline and at 6 weeks and 6 months post-baseline.Results: A total of 51 individuals were randomised (27 to TAU, 24 to TAU plus CBSP) of whom 37 were followed up at 6 months (19 in TAU, 18 in TAU plus CBSP). Engagement, attendance, safety and user feedback indicated that the addition of CBSP to TAU for in-patients who are acutely suicidal was feasible and acceptable while on in-patient wards and following discharge. Economic analysis suggests the intervention could be cost-effective.Discussion: Psychological therapy can be delivered safely to patients who are suicidal although modifications are required for this setting. Findings indicate a larger, definitive trial should be conducted.Declaration of interest: The trial was hosted by Greater Manchester Mental health NHS Trust (formerly, Manchester Mental Health and Social Care NHS Trust). The authors are affiliated to the University of Manchester, Greater Manchester Mental Health Foundation Trust, Lancashire Care NHS Foundation trust and the Manchester Academic Health Sciences Centre. Y.A. is a trustee for a North-West England branch of the charity Mind.


  • Open Access

    A qualitative analysis of suicidal psychiatric inpatients views and expectations of psychological therapy to counter suicidal thoughts, acts and deaths

    by Yvonne F Awenat, Sarah Peters, Patricia A Gooding, Daniel Pratt, Emma Shaw-Núñez, Kamelia Harris, Gillian Haddock

    Suicide is a global problem and suicidal behavior is common in acute psychiatric wards. Inpatient suicides regularly occur with 10.4/100,000 such deaths recorded in the UK in 2016. Inpatient suicides are potentially the most avoidable of all suicides as inpatients have 24-h staff contact. Current inpatient treatment prioritizes maintenance of physical safety by observation, medication and general supportive measures, however efficacious and effective specific treatments are lacking. Psychological treatments have a growing evidence base for suicide prevention yet provision of inpatient therapy is uncommon. The present qualitative study aimed to understand the patient acceptability issues by investigating suicidal inpatients views and expectations of a novel suicide-focussed cognitive behavioural psychological therapy which was nested alongside a pilot clinical trial of the intervention. Thematic analysis of semi-structured individual qualitative interviews with twenty suicidal psychiatric inpatients to investigate their views and expectations about ward-based suicide-focused psychological treatment. Two main themes were identified. The first, ā€˜A therapy that works’, revealed inpatients’ views of the necessary components for effective ward-based suicide-focused psychological therapy. The second, ā€˜Concerns about in-patient suicide-focused therapy’, depicted their fears about engaging in this treatment. Results suggested that suicide-focused psychological therapy was cautiously welcomed by inpatients’ whose narratives expressed their needs, priorities and concerns. Further data analysis enabled formation of a user-informed model of suicide-focussed psychological therapy which offers guidance for researchers and clinicians. We conclude that hospitalization of suicidal individuals offers a critical opportunity to intervene with effective treatment to preserve life and that suicide-focussed psychological therapy is likely to be well received by suicidal inpatients warranting further testing with a sufficiently powered definitive trial. It is important that provision of ward-based psychological therapy for suicidal inpatients addresses the considerable context-specific challenges inherent in this setting. ISRCTN 17890126 , Registry: UK Clinical Trials Gateway, Date of registration: 22/04/15, Date of enrolment of first participant to the trial: 20/05/14 (retrospectively registered).


  • Clinician perspectives on supporting adults with psychosis who wish to discontinue neuroleptic medication: qualitative analysis

    byĀ Nicola Forsberg, Sara Tai, Yvonne Awenat

    Purpose: Research consistently demonstrates that service-users perceive limited choice in whether neuroleptic medication should be dis- continued. Clinicians identify barriers to making shared decisions around medication; however, little is known about how clinical decisions are made regarding whether to support service-users in discontinuing neuroleptic medication. This study examined clinicians’ perspectives on supporting adults who wish to discontinue neuroleptic medication. Materials and Methods: Grounded theory was used to investigate the views and perspectives of clinicians by individual in-depth interviews. Results and Conclusions: A theoretical model (Figure 1) was developed depicting a complex process of decision-making for clinicians working with service-users wishing to discontinue neuroleptics. Decision-making was influenced by clinicians’ personal and professional experiences, and underpinned by their assessment of risk factors and anticipated prognoses for service- users wishing to discontinue neuroleptics. This determined whether clinicians adopted a collaborative or coercive communication style with service-users. Decisions to support discontinuation elicited a range of anxieties in clinicians, leading to actions focused on harm reduction. Decisions about neuroleptic discontinuation are subjective and dependent on clinicians’ previous experiences and judgements regarding potential risk factors. The development of national guidelines, training, resources and support services are required for clinicians to be able to effectively support service-users to discontinue neuroleptic medication.